Books > Medicine > Clinical & internal medicine > Haematology
|
Buy Now
Advances in Biology and Therapy of Multiple Myeloma - Volume 1: Basic Science (Hardcover, 2013 ed.)
Loot Price: R4,529
Discovery Miles 45 290
|
|
Advances in Biology and Therapy of Multiple Myeloma - Volume 1: Basic Science (Hardcover, 2013 ed.)
Expected to ship within 10 - 15 working days
|
Despite the advances in conventional, novel agent and high dose
chemotherapy multiple myeloma (MM) remains incurable. In order to
overcome resistance to current therapies and improve patient
outcome, novel biologically-based treatment approaches are being
developed. Current translational research in MM focusing on the
development of molecularly-based combination therapies has great
promise to achieve high frequency and durable responses in the
majority of patients. Two major advances are making this goal
possible. First, recent advances in genomics and proteomics in MM
have allowed for increased understanding of disease pathogenesis,
identified novel therapeutic targets, allowed for molecular
classification, and provided the scientific rationale for combining
targeted therapies to increase tumor cell cytotoxicity and abrogate
drug resistance. Second, there is now an increased understanding of
how adhesion of MM cells in bone marrow (BM) further impacts gene
expression in MM cells, as well as in BM stromal cells (BMSCs). As
a result of these advances in oncogenomics on the one hand and
increased understanding of the role of the BM in the pathogenesis
of MM on the other, a new treatment paradigm targeting the tumor
cell and its BM microenvironment to overcome drug resistance and
improve patient outcome has now been developed. Thalidomide,
lenalidomide, and Bortezomib are three agents which target the
tumor cell in its microenvironment in both laboratory and animal
models and which have rapidly translated from the bench to the
bedside. Ongoing efforts are using oncogenomics and cell signaling
studies to identify next generation of therapies in MM on the one
hand, and to inform the design of combination trials on the other.
This new paradigm for overcoming drug resistance and improving
patient outcome in MM has great promise not only to change the
natural history of MM, but also to serve as a model for targeted
therapeutics directed to improve outcome of patients with MM.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
You might also like..
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.